|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
|
27780719 |
2017 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
SPOP is mutated in 4.6% to 14.4% of patients with prostate cancer across different ethnic and demographic backgrounds.
|
24563616 |
2014 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
SPOP mutations contribute to prostate cancer development by altering the steady-state levels of key components in the androgen-signaling pathway.
|
25058385 |
2014 |
|
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
SPOP was found to be strongly down-regulated in PCa (median=0.24; range=0.04-9.98) and its expression was associated with both, biochemical (p=0.003) and clinical progression free survival (p=0.023), the very low SPOP expression levels being associated to the worst prognosis.
|
25204806 |
2014 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
SPOP has been shown to be responsible for oncogene SRC-3 ubiquitination and proteolysis in prostate cancers.
|
29461588 |
2018 |
|
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
|
31090082 |
2019 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Altogether, we have revealed a novel mechanism for SPOP in suppressing prostate cancer and provided evidence to show SPOP has dual functions in prostate cancer and CCRC.
|
30237511 |
2019 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
|
25274033 |
2014 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Class-1 activating mutations originate in early prostate cancer without alterations in ETS or SPOP, selectively recur within the wing-2 region of the DNA-binding forkhead domain, enable enhanced chromatin mobility and binding frequency, and strongly transactivate a luminal androgen-receptor program of prostate oncogenesis.
|
31243372 |
2019 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
CTD_human |
Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
|
29295717 |
2018 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Disability or mutation of the SPOP gene has been reported to contribute to prostate cancer incidence and prognosis.
|
31392082 |
2019 |
|
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
FABP5 overexpression is frequent in PCa, but seems to be restricted to TMPRESS2:ERG fusion-negative tumors and is associated with SPOP and FOXA1 mutations.
|
30701334 |
2020 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Finally, we showed that cells formed tumors when re-introduced into mice, providing an authentic in vitro-in vivo preclinical model of a subtype of prostate cancer with a hypermutator phenotype and an SPOP mutation.
|
24998678 |
2014 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Further studies with increased sample size are needed to validate the clinicopathological significance of these SPOP mutations in AA-PCa.
|
24994784 |
2015 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, the authors show that a non-coding polymorphic regulatory element at 7p14.3 may predispose to SPOP mutant prostate cancer subclass through a hormone dependent DNA damage response.
|
28663546 |
2017 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, we analyzed changes in the ubiquitin landscape induced by prostate cancer-associated mutations of SPOP, an E3 ubiquitin ligase substrate-binding protein.
|
25278611 |
2014 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, we identified a previously unrecognized mutation Q165P at the edge of SPOP MATH domain in primary and metastatic PCa of a patient.
|
31559706 |
2019 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we report that NANOG is degraded by SPOP, a frequently mutated tumor suppressor of PCa.
|
30595535 |
2019 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
However, how SPOP mutations contribute to prostate cancer pathogenesis remains poorly understood.
|
28448495 |
2017 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Importantly, cancer-derived mutations in SPOP or at the Nanog-degron (S68Y) disrupt SPOP-mediated destruction of Nanog, leading to elevated cancer stem cell traits and PrCa progression.
|
30595538 |
2019 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In mouse prostate organoids, mutant SPOP drove increased proliferation and a transcriptional signature consistent with human prostate cancer.
|
28292441 |
2017 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
In summary, PRISM-SRM enables multiplexed, isoform-specific detection of mutant SPOP proteins in cell lysates, providing significant potential in biomarker development for prostate cancer.
|
28810879 |
2017 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In summary, we found no evidence that ERG is an effector of SPOP mutation in human prostate cancer or mouse models.
|
29202479 |
2018 |